Literature DB >> 3198133

Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).

G Masucci1, C Lindemalm, J E Frödin, B Hagström, H Mellstedt.   

Abstract

Peripheral blood mononuclear cells (PBMC) from healthy individuals were studied for their lytic capability in ADCC using SW948 (a human colorectal carcinoma cell line) as target cells. Three monoclonal antibodies (MAbs) were used: two mouse MAbs (IgG2A) against the antigenic structures CO17-1A and BR55-2 respectively and one chimeric MAb 17-1A (IgG1) (mouse-human). Three kinds of effector cells were prepared. PBMC were purified on a Ficoll-Isopaque gradient (FIP cells) (a mixture of lymphocytes and monocytes). To obtain pure monocytes (greater than 90%), PBMC were centrifuged on a Nycodenz gradient (Nycodenz cells). Highly purified lymphocytes (greater than 98%) were obtained by treatment of FIP cells with iron powder and removal of phagocytic cells (PBL cells). Monocytes had the highest lytic capability. FIP cells were less effective than monocytes. PBL cells had the poorest killing activity. In reconstitution experiments addition of increasing amount of monocytes to PBL resulted in an augmented cytotoxicity. The numbers of Leu-M3+ cells, Leu-M5+ cells (monocytes) and CD16+ cells correlated positively to cytotoxicity. Higher concentration of MAb 17-1A was required to reach the same level of cytotoxicity using FIP cells as effector cells as compared to monocytes. MAb BR55-2 induced the same cytotoxic activity as MAb 17-1A. Combination of these two MAbs did not increase the lytic capability. Chimeric MAb 17-1A mediated ADCC in a dose-dependent fashion. The chimeric MAb was consistently more effective than the mouse MAb.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3198133     DOI: 10.1089/hyb.1988.7.429

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  16 in total

1.  Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).

Authors:  G Masucci; P Ragnhammar; P Wersäll; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.

Authors:  P Ragnhammar; G Masucci; J E Frödin; A L Hjelm; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.

Authors:  F J Primus; T K Pendurthi; P Hutzell; S Kashmiri; D C Slavin; R Callahan; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  P Wersäll; G Masucci; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  G Masucci; P Wersäll; P Ragnhammar; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A.

Authors:  Y Haga; C L Sivinski; D Woo; M A Tempero
Journal:  Int J Pancreatol       Date:  1994-02

Review 7.  Chemotherapy and immunotherapy of colorectal cancer.

Authors:  G Masucci; P Ragnhammar; J E Frödin; A L Hjelm; P Wersäll; J Fagerberg; A Osterborg; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

8.  The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).

Authors:  P Ragnhammar; I Magnusson; G Masucci; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

9.  Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.

Authors:  Wei Xiang; Pauline Wimberger; Torsten Dreier; Joachim Diebold; Doris Mayr; Patrick A Baeuerle; Rainer Kimmig
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-18       Impact factor: 4.553

10.  ING-1(heMAb), a monoclonal antibody to epithelial cell adhesion molecule, inhibits tumor metastases in a murine cancer model.

Authors:  Harry H Ruan; Kristen R Scott; Eddie Bautista; W Steve Ammons
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.